Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease
Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort
Objective: To study problems faced by PD patients during lockdown due lack of healthcare and medication procurement and address such problems using telemedicine via virtual…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…Beta-antagonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of β-antagonist and the risk of PD.…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD).…Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting
Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 34
- Next Page »